What Should You know About Rain Therapeutics (RAIN) Before Investing?

By Harris Dyer • Wednesday, August 09 13:46 • Permanent Link

Rain Therapeutics moved -3.2% this afternoon session, trading between a high of $1.25 and a low of $1.16 per share. Yesterday the stock finished at $1.25 per share, compared to an average analyst target price of $5.81.

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. Rain Therapeutics has trailing twelve months earnings per share (EPS) of -2.46, which at today's prices amounts to a price to earnings (P/E) ratio of -0.5.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.